5,6-Dihydropyran-2-ones Possessing Various Sulfonyl Functionalities: Potent Nonpeptidic Inhibitors of HIV Protease
F Boyer(Pfizer (United States)), John W. Erickson(National Institutes of Health), Alexander Palovsky(Pfizer (United States)), Tod P. Holler(Pfizer (United States)), James M. Sanders(Southwestern Medical Center), Sergei Gulnik(Beckman Coulter Foundation), Larry J. Markoski(Pfizer (United States)), Christopher Gajda(Pfizer (United States)), Greg Zeikus(Pfizer (United States)), K. R. Krishna Iyer(University of Michigan), Susan E. Hagen(Pfizer (United States)), Elizabeth A. Lunney(Pfizer (United States)), Edmund L. Ellsworth(Pfizer (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Carolyn Nouhan(Pfizer (United States)), Joanne Brodfuehrer(Pfizer (United States)), Neil M.H. Graham(UK Dementia Research Institute), Michael Sinz(Rutgers, The State University of New Jersey), A. Urumov(Pfizer (United States)), Donna Ferguson(Pfizer (United States)), Donald Hupe(Pfizer (United States)), Steven VanderRoest(Pfizer (United States)), J. V. N. Vara Prasad(Pfizer (United States)), Bradley D. Tait(Pfizer (United States)), Stephen J. Gracheck(Pfizer (United States)), John M. Domagala(Pfizer (United States)), Eric Zeikus(Pfizer (United States))
Cited by 51
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k